Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Problems and emerging approaches in HIV/AIDS vaccine development.
Titti F, Cafaro A, Ferrantelli F, Tripiciano A, Moretti S, Caputo A, Gavioli R, Ensoli F, Robert-Guroff M, Barnett S, Ensoli B. Titti F, et al. Expert Opin Emerg Drugs. 2007 Mar;12(1):23-48. doi: 10.1517/14728214.12.1.23. Expert Opin Emerg Drugs. 2007. PMID: 17355212 Review.
Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P.
Cafaro A, Bellino S, Titti F, Maggiorella MT, Sernicola L, Wiseman RW, Venzon D, Karl JA, O'Connor D, Monini P, Robert-Guroff M, Ensoli B. Cafaro A, et al. J Virol. 2010 Sep;84(17):8953-8. doi: 10.1128/JVI.00377-10. Epub 2010 Jun 16. J Virol. 2010. PMID: 20554774 Free PMC article.
Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.
Florese RH, Wiseman RW, Venzon D, Karl JA, Demberg T, Larsen K, Flanary L, Kalyanaraman VS, Pal R, Titti F, Patterson LJ, Heath MJ, O'Connor DH, Cafaro A, Ensoli B, Robert-Guroff M. Florese RH, et al. Vaccine. 2008 Jun 19;26(26):3312-21. doi: 10.1016/j.vaccine.2008.03.100. Epub 2008 Apr 30. Vaccine. 2008. PMID: 18486283 Free PMC article.
An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.
Gómez-Román VR, Florese RH, Peng B, Montefiori DC, Kalyanaraman VS, Venzon D, Srivastava I, Barnett SW, Robert-Guroff M. Gómez-Román VR, et al. J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):270-7. doi: 10.1097/01.qai.0000230318.40170.60. J Acquir Immune Defic Syndr. 2006. PMID: 16940858
A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
Demberg T, Florese RH, Heath MJ, Larsen K, Kalisz I, Kalyanaraman VS, Lee EM, Pal R, Venzon D, Grant R, Patterson LJ, Korioth-Schmitz B, Buzby A, Dombagoda D, Montefiori DC, Letvin NL, Cafaro A, Ensoli B, Robert-Guroff M. Demberg T, et al. J Virol. 2007 Apr;81(7):3414-27. doi: 10.1128/JVI.02453-06. Epub 2007 Jan 17. J Virol. 2007. PMID: 17229693 Free PMC article.
Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.
Peng B, Wang LR, Gómez-Román VR, Davis-Warren A, Montefiori DC, Kalyanaraman VS, Venzon D, Zhao J, Kan E, Rowell TJ, Murthy KK, Srivastava I, Barnett SW, Robert-Guroff M. Peng B, et al. J Virol. 2005 Aug;79(16):10200-9. doi: 10.1128/JVI.79.16.10200-10209.2005. J Virol. 2005. PMID: 16051813 Free PMC article.
259 results